Skip to main content

Apyx Medical Corp(APYX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Apyx Medical Corporation with Losses of $100,000 to Contact the Firm

Business Wire - Thu Aug 4, 2022

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Apyx Medical Corporation (“Apyx” or “the Company”) (NASDAQ: APYX) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Apyx’s Advanced Energy products were frequently used for off-label indications, representing a significant portion of its sales. These off-label uses led to an increase in the number of adverse event reports filed by the Company. This was likely to lead to regulatory scrutiny. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Apyx, investors suffered damages.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Provided Content: Content provided by Business Wire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe